Gsk2245035

Catalog No. :
ACSWGN385
CAS No. :
1207629-49-9
Molecular Formula :
C20H34N6O2
Molecular Weight :
390.53

IUPAC Name:(S)-6-amino-2-(pentan-2-yloxy)-9-(5-(piperidin-1-yl)pentyl)-7,9-dihydro-8H-purin-8-one

Gsk2245035 structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1mg98%$185.00Login to see priceInquiryInquiry
5mg98%$461.00Login to see priceInquiryInquiry
10mg98%$738.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameGsk2245035
IUPAC Name(S)-6-amino-2-(pentan-2-yloxy)-9-(5-(piperidin-1-yl)pentyl)-7,9-dihydro-8H-purin-8-one
Molecular FormulaC20H34N6O2
Molecular Weight390.53
SMILESO=C1NC2=C(N)N=C(O[C@H](CCC)C)N=C2N1CCCCCN3CCCCC3
InChI KeyLFMPVTVPXHNXOT-HNNXBMFYSA-N
Synonymcompound 32 [PMID: 26861551] | GSK2245035 | GSK-2245035 | CS-0065520 | MS-26512 | LFMPVTVPXHNXOT-HNNXBMFYSA-N | 1207629-49-9 | 6-amino-2-[(2S)-pentan-2-yl]oxy-9-(5-piperidin-1-ylpentyl)-7H-purin-8-one | 5L3SX16QBQ | UNII-5L3SX16QBQ | 8H-Purin-8-one, 6-ami
CAS No.1207629-49-9
PubChem CID44623937

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACSWGN385 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSWGN385 route product structure diagram
    ACSWGN3851207629-49-9
Inquiry

2. ACSWGN385 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSWGN385 route product structure diagram
    ACSWGN3851207629-49-9
Inquiry

Comments (0)